DE69211892D1 - 1-(Pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-Indole, Zwischenprodukte und ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel - Google Patents

1-(Pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-Indole, Zwischenprodukte und ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Info

Publication number
DE69211892D1
DE69211892D1 DE69211892T DE69211892T DE69211892D1 DE 69211892 D1 DE69211892 D1 DE 69211892D1 DE 69211892 T DE69211892 T DE 69211892T DE 69211892 T DE69211892 T DE 69211892T DE 69211892 D1 DE69211892 D1 DE 69211892D1
Authority
DE
Germany
Prior art keywords
loweralkyl
hydrogen
medicaments
chem
oxazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69211892T
Other languages
English (en)
Other versions
DE69211892T2 (de
Inventor
Richard Charles Effland
Larry Davis
Gordon Edward Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Roussel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharmaceuticals Inc filed Critical Hoechst Roussel Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69211892D1 publication Critical patent/DE69211892D1/de
Publication of DE69211892T2 publication Critical patent/DE69211892T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69211892T 1991-04-15 1992-04-09 1-(Pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-Indole, Zwischenprodukte und ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Expired - Fee Related DE69211892T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/684,758 US5214038A (en) 1991-04-15 1991-04-15 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof

Publications (2)

Publication Number Publication Date
DE69211892D1 true DE69211892D1 (de) 1996-08-08
DE69211892T2 DE69211892T2 (de) 1996-12-19

Family

ID=24749434

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69211892T Expired - Fee Related DE69211892T2 (de) 1991-04-15 1992-04-09 1-(Pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-Indole, Zwischenprodukte und ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Country Status (22)

Country Link
US (3) US5214038A (de)
EP (1) EP0509400B1 (de)
JP (1) JP2608359B2 (de)
KR (1) KR100201509B1 (de)
AT (1) ATE140006T1 (de)
AU (1) AU643135B2 (de)
CA (1) CA2065986C (de)
CZ (1) CZ282054B6 (de)
DE (1) DE69211892T2 (de)
DK (1) DK0509400T3 (de)
ES (1) ES2094840T3 (de)
FI (1) FI97544C (de)
GR (1) GR3020612T3 (de)
HU (1) HUT62588A (de)
IE (1) IE74907B1 (de)
IL (1) IL101589A (de)
NO (1) NO301765B1 (de)
NZ (2) NZ242309A (de)
PL (1) PL168671B1 (de)
RU (1) RU2042680C1 (de)
TW (1) TW211016B (de)
ZA (1) ZA922721B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
US5264442A (en) * 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
GB9225859D0 (en) * 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
EP1424325A4 (de) * 2001-09-07 2005-12-21 Ono Pharmaceutical Co Indolderivate, verfahren zu deren herstellung und arzneimittel, die diese als wirkstoff enthalten
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
CN105669540A (zh) 2009-01-28 2016-06-15 卡鲁斯治疗有限公司 Scriptaid电子等排体及其在治疗中的用途
NZ707366A (en) 2012-11-07 2018-11-30 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
RS57816B1 (sr) 2013-05-10 2018-12-31 Karus Therapeutics Ltd Inhibitori histon deacetilaze
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
EP4474017A3 (de) 2018-08-13 2025-02-26 F. Hoffmann-La Roche AG Neue heterocyclische verbindungen
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029657A (en) * 1976-06-14 1977-06-14 The Dow Chemical Company 6,7-Dichloro-3,4-dihydro-2H-pyrazino(2,3-B)(1,4)oxazines
DE2726437A1 (de) * 1977-06-11 1978-12-21 Bayer Ag Hydrazonfarbstoffe
US5039811A (en) * 1987-04-24 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
DE3852335T2 (de) * 1987-04-24 1995-05-11 Hoechst Roussel Pharma N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
US4916135A (en) * 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones
DK0415103T3 (da) * 1989-08-02 1995-06-19 Hoechst Roussel Pharma 2,3-Dihydro-1-(pyridinylamino)-indoler, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines

Also Published As

Publication number Publication date
NO921490D0 (no) 1992-04-14
ZA922721B (en) 1992-11-25
CA2065986C (en) 2006-02-21
FI921641A7 (fi) 1992-10-16
KR920019796A (ko) 1992-11-20
NO301765B1 (no) 1997-12-08
US5519131A (en) 1996-05-21
JPH05112572A (ja) 1993-05-07
AU1485292A (en) 1992-10-22
EP0509400A1 (de) 1992-10-21
CA2065986A1 (en) 1992-10-16
DK0509400T3 (da) 1996-10-28
PL294221A1 (en) 1993-08-09
FI97544C (fi) 1997-01-10
IL101589A0 (en) 1992-12-30
RU2042680C1 (ru) 1995-08-27
PL168671B1 (pl) 1996-03-29
ES2094840T3 (es) 1997-02-01
AU643135B2 (en) 1993-11-04
HU9201290D0 (en) 1992-07-28
FI921641A0 (fi) 1992-04-13
US5214038A (en) 1993-05-25
IE921190A1 (en) 1992-10-21
ATE140006T1 (de) 1996-07-15
US5276156A (en) 1994-01-04
CZ282054B6 (cs) 1997-05-14
NZ242309A (en) 1995-07-26
CS113592A3 (en) 1992-11-18
TW211016B (de) 1993-08-11
DE69211892T2 (de) 1996-12-19
NO921490L (no) 1992-10-16
FI97544B (fi) 1996-09-30
IE74907B1 (en) 1997-08-13
HUT62588A (en) 1993-05-28
IL101589A (en) 1996-10-31
KR100201509B1 (ko) 1999-06-15
JP2608359B2 (ja) 1997-05-07
NZ248131A (en) 1995-07-26
GR3020612T3 (en) 1996-10-31
EP0509400B1 (de) 1996-07-03

Similar Documents

Publication Publication Date Title
DE69211892D1 (de) 1-(Pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-Indole, Zwischenprodukte und ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE3772905D1 (de) Alpha-alkyl-4-amino-3-chinolin-methanole und 1-(4-aralkylamino-3-chinolyl)alkanone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE69032020D1 (de) N-Substituierte 4-Pyrimidinamine und -Pyrimidindiamine, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE69025941D1 (de) Dem Physostigmin verwandte 4- und 6-Carbamate, ein Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69130196D1 (de) 1-(Substituierte Pyridinylamino)-1H-indol-5-yl substituierte Carbamate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69206889D1 (de) Arylalkylpiperidine-4-yl)methyl]-2-alpha-3,4,5-tetrahydro-1-(2H)-acenaphthylene-1-Onederivate, ein Verfahren für ihre Herstellung und ihre Verwendung als Medikamente
DE3780015D1 (de) Kondensierte heterocyclische tetrahydroaminochinolinole und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE68918402D1 (de) 1,2,3,4-Tetrahydro-1,9-Acridindiamine, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE3671017D1 (de) Benzo(c)-1,5-naphthyridine, ein verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE104298T1 (de) Kondensierte heterocyclische derivate von 1,2,3,4-tetrahydroacridin, verfahren zu ihrer herstellung und ihre verwendung als medikament.
DE69019066D1 (de) 4,5,5a,6-Tetrahydro-3H-isoxyzolo(5,4,3-k1)acridinderivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE69131546D1 (de) Pyrido[3,4-b]pyrrolo[1,2-e][1,4,5]oxadiazepine und verwandte Analoge, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee